20260420_TIRZ_5MG.png
20260420_TIRZ_10MG.png
20260420_TIRZ_5MG.png
20260420_TIRZ_10MG.png

Tirzepatide

from $124.00

Full Name: Tirzepatide

CAS Number: 2023788-19-2

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: 4,813.52 g/mol

Appearance: White lyophilized powder

Solubility: Water-soluble (pH-dependent)

Storage: -20°C, desiccated, protected from light

Size:

Full Name: Tirzepatide

CAS Number: 2023788-19-2

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: 4,813.52 g/mol

Appearance: White lyophilized powder

Solubility: Water-soluble (pH-dependent)

Storage: -20°C, desiccated, protected from light

Research Context

Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly, representing a novel approach in incretin pharmacology. It was designed to activate both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously — the first approved molecule to demonstrate this dual mechanism.

For researchers, tirzepatide is significant as a tool compound for studying dual-incretin receptor pharmacology and as a case study in peptide engineering. Its structure incorporates a C20 fatty diacid moiety for albumin binding and half-life extension, and several non-natural amino acid substitutions. The analytical characterization of tirzepatide is a meaningful exercise in peptide HPLC method development given its molecular complexity.

Key References

  1. Coskun T, et al. (2018). "LY3298176, a novel dual GIP and GLP-1 receptor agonist." Mol Metab. 18:3-14. PMID: 30473097

  2. Frías JP, et al. (2021). "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." N Engl J Med. 385(6):503-515. PMID: 34170647

  3. Jastreboff AM, et al. (2022). "Tirzepatide once weekly for the treatment of obesity." N Engl J Med. 387(4):327-340. PMID: 35658024